T cell responses detected in spontaneously resolved patients
| HCV genotype-3-specific T cell response detected in spontaneous resolved patients | Number of patients responding to epitope | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Viral region | AA position | Sequence | HLA | CD4/CD8 | Pept. set | S | C | A | Total |
| Core | 27–51 | GGQIVGGVYVLPRRGPRL VYVLPRRGPRLGVRATRK | ND | ND | OP | 1 | 2 | – | 3 |
| 143–158 | IPLVGAPVGGVARALAH | ND | CD4 | OPs | 1 | – | – | 1 | |
| E2 | 610–625 | LTPRCMVDYPYRLWHY | ND | ND | OPs | 2 | 1 | – | 3 |
| 702–719 | NIVDVQYLYGVGSGMVGW | ND | CD8 | OPs | 2 | – | 1TxN | 3 | |
| NS2 | 931–940 | LVRSVMGGKY | A03 | CD8 | HLA | 1 | – | – | 1 |
| NS3 | 1040–1062 | AQQTRGLLGTIVTSLTGR LGTIVTSLTGRDKNVV | ND | ND | OPs | 1 | – | – | 1 |
| 1139–1147 | LVTRDADVI | A03 | CD8 | HLA | 1 | – | – | 1 | |
| 1198–1213 | KALQFIPVETLSTQAR | ND | ND | OPs | 1 | – | – | 1 | |
| 1246–1261 | KVPAAYVAQGYNVLVL | ND | ND | OPs | 1 | – | – | 1 | |
| 1264–1281 | SVAATLGFGSFMSRAYGI | ND | ND | OPs | 1 | – | 1UK | 2 | |
| 1282–1305 | DPNIRTGNRTVTTGAKL GNRTVTTGAKLTYSTYGK | ND | ND | OPs | 2 | – | – | 2 | |
| 1379–1387 | IPFYGKAIPI | B51 | CD8 | HLA | – | – | 1SR 1TxS | 2 | |
| 1423–1440 | AYYRGLDVSVIPTAGDVV | ND | CD4 | OPs | 1 | 1 | – | 2 | |
| 1520–1537 | RPSGMFDSVVLCECYDA DSVVLCECYDAGCSWYDL | ND | CD8 | OPs | 2 | 12 | – | 14 | |
| NS4b | 1805–1822 | TSPLTTNQTMFFNILGGW | ND | ND | OPs | 2 | – | – | 2 |
| 1853–1862 | RVLLDILAGY | A26 | CD8 | HLA | – | 3 | 1TxS 1SR | 5 | |
| NS5a | 2126–2141 | AEFFTEVDGVRLHRYA | ND | CD8 | OPs | 2 | – | 2TxS | 4 |
| NS5b | 2508–2516 | RVKARMLTI | B08 | CD8 | HLA | 1 | – | 1TxS | 2 |
| 2548–2565 | NQIRSVWEDLLEDTTTPI | ND | CD4 | OPs | 1 | – | – | 1 | |
| 2603–2618 | KRALYDVIQKLSIETM | ND | CD4 | OPs | 1 | – | – | 1 | |
| 2844–2861 | IMYAPTIWVRMVMMTHFF | ND | ND | OPs | – | – | 1SR | 1 | |
| 2893–2908 | IIERLHGLSAFTLHSY | ND | CD4 | OPs | 1 | – | – | 1 | |
T cell targets detected in spontaneously resolved patients and patients acutely infected who subsequently resolved infection spontaneously. For each targeted epitope, the amino acid (AA) position, peptide sequence, restricting HLA type, CD4/CD8 restriction and detecting peptide sets are specified. The total number of patients responding to the peptide and their status of infection (S, spontaneously resolved; C, chronic; A, acute; TxS, treated achieving SVR (sustained virological response); TxN, not responding to treatment; SR, spontaneously resolved) is detailed. Underlining represents amino acids that are common between overlapping peptides.
ND, not determined; OPs, overlapping peptides.